SlideShare una empresa de Scribd logo
1 de 129
Neurology Archer  USMLE Step3 Reviews www.CcsWorkshop.com Archer Slides are intended for use with Archer USMLE step 3 video lectures. Hence, most  slides are very brief summaries of the concepts which will be addressed in a detailed way with focus on High-yield concepts in the Video lectures.  These slides are only SAMPLES
Risk Factors - Stroke ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Primary Prevention Of Stroke ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Primary Prevention Of Stroke ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Primary Prevention - Stroke ,[object Object]
Stroke - Management ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Stroke - Management ,[object Object],[object Object],[object Object],[object Object],[object Object]
Stroke - Thrombolytics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Thrombolysis Protocol ,[object Object],[object Object],[object Object],[object Object],[object Object]
Stroke – Other Rx ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Stroke Prevention – Antiplatelet therapy comparision ,[object Object],[object Object],[object Object]
Stroke – Other Rx/ Secondary Prevention ,[object Object],[object Object],[object Object],[object Object],[object Object]
Carotid Stenosis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Symptomatic Carotid Stenosis -Mx ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Asymptomatic Carotid Stenosis > 60% - Management ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Hemorrhagic Stroke ,[object Object],[object Object],[object Object]
Intracerebral Hemorrhage (ICH) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Subarachnoid Hemorrhage ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Meningitis
Meningitis  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Meningitis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Meningitis
Meningitis – Empiric Rx ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Meningitis – Emperical therapy Predisposing Factor AGE Common Bacterial Pathogens Antimicrobial Rx <1 month  Streptococcus agalactiae, Escherichia coli, Listeria monocytogenes, Klebsiella  species  Ampicillin plus cefotaxime or ampicillin plus an aminoglycoside  1 - 23 months  Streptococcus pneumoniae , Neisseria meningitidis, S. agalactiae, Haemophilus influenzae, E. coli   Vancomycin plus a third-generation cephalosporin  2- 50 years  N . meningitidis, S. pneumoniae   Vancomycin plus a third-generation cephalosporin  >50 years  S. pneumoniae, N. meningitidis,  L. monocytogenes ,  aerobic gram-negative bacilli  Vancomycin plus  ampicillin  plus a third-generation cephalosporin
Meningitis – Emperical therapy Predisposing Factor HEAD TRAUMA Common Bacterial Pathogens Antimicrobial Rx   Basilar skull fracture  S. pneumoniae, H. influenzae,  group A  -hemolytic streptococci  Vancomycin plus a third-generation cephalosporin  Penetrating trauma  Staphylococcus aureus,  coagulase-negative staphylococci (especially  Staphylococcus epidermidis),  aerobic gram-negative bacilli (including  Pseudomonas aeruginosa )   Vancomycin plus cefepime, vancomycin plus ceftazidime, or vancomycin plus meropenem    YOU ARE Adding an antipseudomonal antibiotic. Postneurosurgery  Aerobic gram-negative bacilli (including  P. aeruginosa ), S . aureus , coagulase-negative staphylococci (especially  S. epidermidis)   Vancomycin plus cefepime, vancomycin plus ceftazidime, or vancomycin plus meropenem  CSF shunt  Coagulase-negative staphylococci (especially  S. epidermidis), S. aureus,  aerobic gram-negative bacilli (including  P. aeruginosa ), Propionibacterium acnes   Vancomycin plus cefepime,c vancomycin plus ceftazidime,c or vancomycin plus meropenem
Fall Prevention - Elderly
FALLS IN ELDERLY ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Screening and Evaluation for fall risk ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Get up and Go Test ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fall Risk - Prevention ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fall Risk Prevention ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fall Risk Prevention ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Headaches Migraines Tension headaches Cluster Headaches Temporal arteritis Chronic daily headache Analgesic Rebound Headache Post Traumatic Headache Menstrual Migraine Sinusitis
Migraines
Migraines - Features ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Migraine - Features ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Post-test Probabilities of Migraine Based on the Number of Migraine Features on History Compared to a Reference Standard of Headache Expert Neurologist Clinical Evaluation Result Pretest Probability (%)† 20 50 80 0, 1, or 2 migraine symptoms* 5 15 50 3 migraine symptoms* 75 94 99 4 or 5 migraine symptoms* 90 96 >99
Migraine - Diagnosis ,[object Object],[object Object],[object Object]
Migraines - Rx ,[object Object],[object Object]
Migraines – Drug Rx
Acute Migraine Rx
Drug Rx ,[object Object],[object Object],[object Object],[object Object],[object Object]
Preventive rx ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Referral ,[object Object],[object Object],[object Object],[object Object]
Cluster Headaches
Cluster Headaches  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Cluster Headache - Physical ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Investigations ,[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Trigeminal Neuralgia
Clinical features ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical Features ,[object Object],[object Object]
Treatment ,[object Object]
Treatment ,[object Object],[object Object],[object Object],[object Object]
Tension Headache
Tension Headaches ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object]
Chronic Daily Headache Rebound Headaches Analgesic overuse headaches Chronic Migraine
CDH ,[object Object],[object Object],[object Object]
CDH – d/d  Primary Headaches Headache Duration > 4hrs Headache Duration < 4hrs Chronic (transformed) migraine Strictly unilateral-prominent autonomic features(SUNCT) Chronic tension-type headache Cluster headache New daily persistent headache Paroxysmal hemicrania  Hemicrania continua Trigeminal neuralgia Cough headache Benign exertional headache Headache associated with sexual activity
CDH – d/d  Secondary Headaches ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CDH ,[object Object],[object Object],[object Object],[object Object],[object Object]
Drug rebound & Medication overuse ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical Approach in Patients with Chronic Daily Headache ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment of Medication Overuse (Drug Rebound Headache) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Benign Intracranial Hypertension Pseudotumor Cerebrii
Pseudotumor Cerebri ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Bell’s Palsy
Bells Palsy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Bells Palsy – Clues in Hx ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Bells Palsy – Clues in Physical ,[object Object],[object Object],[object Object],[object Object]
Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment ,[object Object],[object Object],[object Object],[object Object]
Follow-up ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Multiple Sclerosis
Symptoms n Signs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
M.S Classification ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
Revised McDonald Criteria for Diagnosis of MS
Definition of positive MRI—3 out of 4 of the following: 1 gadolinium-enhancing lesion or 9 T2 hyperintense lesions if no gadolinium-enhancing lesion; 1 or more infratentorial lesions; 1 or more juxtacortical lesions; 3 or more periventricular lesions. Note: A spinal cord lesion can be considered equivalent to an infratentorial lesion in the brain. Thus, an enhancing spinal cord lesion is considered to be equivalent to an enhancing brain lesion, and individual spinal cord lesions can contribute together with individual brain lesions to reach the required number of T2 lesions. Clinical (Attacks) Objective Lesions Additional Requirements to Make Diagnosis 2 or more 2 or more None; additional evidence desirable but must be consistent with MS 2 or more 1 Dissemination in space by MRI  or  positive CSF and 2 or more MRI lesions consistent with MS  or  further clinical attack involving different site 1 2 or more Dissemination in time by MRI  or  second clinical attack 1 (monosymptomatic) 1 Dissemination in space by MRI  or  positive CSF and 2 or more MRI lesions consistent with MS AND Dissemination in time by MRI  or  second clinical attack 1 (progression from onset) 1 One year of disease progression (retrospectively or prospectively determined) AND Two of the following: a) Positive brain MRI (nine T2 lesions or four or more T2 lesions with positive visual evoked potentials) b) Positive spinal cord MRI (two focal T2 lesions) c) Positive CSF
MS - Admission ,[object Object],[object Object],[object Object]
Treatment ,[object Object],[object Object]
Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Follow-Up ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Myasthenia Gravis
Symptoms N Signs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diagnosis ,[object Object],[object Object]
Differential Diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment ,[object Object],[object Object]
Drug induced Myasthenia ,[object Object]
ALS
Symptoms ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Signs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diagnosis ,[object Object],[object Object]
Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Neurosyphilis Refer to ID slides under “Syphilis”
Delirium Refer to Psychaitry Slides
Dementia
Risk Factors for Dementia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Physical exam ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
D/D = Dementia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Vascular dementia ,[object Object],[object Object],[object Object],[object Object],[object Object]
CJD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
HIV Dementia ,[object Object],[object Object],[object Object]
NPH ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Delirium vs. Dementia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Alzheimer’s Disease ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Alzheimers - diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drug therapy - Dementia ,[object Object],[object Object],[object Object],[object Object],[object Object]
Drug therapy - Dementia ,[object Object],[object Object],[object Object],[object Object]
Drug Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drug therapy - Pseudodementia ,[object Object],[object Object],[object Object],[object Object],[object Object]
Driving - Dementia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
END Questions?
Seizure disorders
Parkinson disease
Narcolepsy and cataplexy
insomnia
Guilliane-barre syndrome
Peripheral neuropathies
Carpal tunnel syndrome ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Movement Disorders ,[object Object],[object Object],[object Object],[object Object]

Más contenido relacionado

La actualidad más candente

DUAL ANTIPLATELET THERAPY
DUAL ANTIPLATELET THERAPYDUAL ANTIPLATELET THERAPY
DUAL ANTIPLATELET THERAPY
drskd6
 
Blood transfusion
Blood transfusion Blood transfusion
Blood transfusion
Hassan Taha
 

La actualidad más candente (20)

AHA/ASA Guidelines for Ischemic Stroke
AHA/ASA Guidelines for Ischemic StrokeAHA/ASA Guidelines for Ischemic Stroke
AHA/ASA Guidelines for Ischemic Stroke
 
I. Med OSCE STATIONS_044558.pptx
I. Med OSCE  STATIONS_044558.pptxI. Med OSCE  STATIONS_044558.pptx
I. Med OSCE STATIONS_044558.pptx
 
Antiplatelet in acute coronary syndrome
Antiplatelet in acute coronary syndrome Antiplatelet in acute coronary syndrome
Antiplatelet in acute coronary syndrome
 
Massive Blood Transfusion
Massive Blood TransfusionMassive Blood Transfusion
Massive Blood Transfusion
 
New oral anticoagulants (NOAC) WATAG guidelines
New oral anticoagulants (NOAC) WATAG guidelinesNew oral anticoagulants (NOAC) WATAG guidelines
New oral anticoagulants (NOAC) WATAG guidelines
 
DUAL ANTIPLATELET THERAPY
DUAL ANTIPLATELET THERAPYDUAL ANTIPLATELET THERAPY
DUAL ANTIPLATELET THERAPY
 
Antiplatelet Therapy: What’s New, Older Agents and How They Work
Antiplatelet Therapy: What’s New, Older Agents and How They WorkAntiplatelet Therapy: What’s New, Older Agents and How They Work
Antiplatelet Therapy: What’s New, Older Agents and How They Work
 
Stroke Made EASY
Stroke Made EASYStroke Made EASY
Stroke Made EASY
 
Prevention of recurrent stroke in atrial fibrillation Jacek Staszewski
Prevention of recurrent stroke in atrial fibrillation Jacek StaszewskiPrevention of recurrent stroke in atrial fibrillation Jacek Staszewski
Prevention of recurrent stroke in atrial fibrillation Jacek Staszewski
 
Picture Medicine
Picture MedicinePicture Medicine
Picture Medicine
 
OSCE Stations For MBBS
OSCE Stations For MBBSOSCE Stations For MBBS
OSCE Stations For MBBS
 
Fluids in Intensive Care
Fluids in Intensive Care Fluids in Intensive Care
Fluids in Intensive Care
 
Prevention of Venous Thromboembolism
Prevention of Venous ThromboembolismPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism
 
Blood transfusion
Blood transfusion Blood transfusion
Blood transfusion
 
ADA GUIDELINE.pptx
ADA GUIDELINE.pptxADA GUIDELINE.pptx
ADA GUIDELINE.pptx
 
Sepsis update 2021
Sepsis update 2021Sepsis update 2021
Sepsis update 2021
 
Hypertension Guidelines JNC 8
Hypertension Guidelines JNC 8Hypertension Guidelines JNC 8
Hypertension Guidelines JNC 8
 
POCUS in critical care Jan 8th 2020 Teh Iran
POCUS in critical care Jan 8th 2020 Teh IranPOCUS in critical care Jan 8th 2020 Teh Iran
POCUS in critical care Jan 8th 2020 Teh Iran
 
2022 Hypertension Lecture (Updated Guidelines).pdf
2022 Hypertension Lecture (Updated Guidelines).pdf2022 Hypertension Lecture (Updated Guidelines).pdf
2022 Hypertension Lecture (Updated Guidelines).pdf
 
BLS(basic life support) & ACLS with PALS by Dr. Shailendra
BLS(basic life support) & ACLS with PALS by Dr. ShailendraBLS(basic life support) & ACLS with PALS by Dr. Shailendra
BLS(basic life support) & ACLS with PALS by Dr. Shailendra
 

Destacado

50 star ccs cases usmle forums
50 star ccs cases   usmle forums50 star ccs cases   usmle forums
50 star ccs cases usmle forums
Johongir Muradov
 

Destacado (16)

Archer USMLE Step 3 CCS workshop 2018
Archer USMLE Step 3 CCS workshop 2018Archer USMLE Step 3 CCS workshop 2018
Archer USMLE Step 3 CCS workshop 2018
 
Psychiatry - Archer USMLE step 3
Psychiatry - Archer USMLE step 3Psychiatry - Archer USMLE step 3
Psychiatry - Archer USMLE step 3
 
Nephrology - ARCHER USMLE STEP 3
Nephrology - ARCHER USMLE STEP 3Nephrology - ARCHER USMLE STEP 3
Nephrology - ARCHER USMLE STEP 3
 
Endocrinology - Archer USMLE step 3
Endocrinology - Archer USMLE step 3Endocrinology - Archer USMLE step 3
Endocrinology - Archer USMLE step 3
 
Archer Dermatology USMLE step 3
Archer Dermatology USMLE step 3Archer Dermatology USMLE step 3
Archer Dermatology USMLE step 3
 
Ethics in medicine - Archer USMLE step 3
Ethics in medicine - Archer USMLE step 3Ethics in medicine - Archer USMLE step 3
Ethics in medicine - Archer USMLE step 3
 
50 star ccs cases usmle forums
50 star ccs cases   usmle forums50 star ccs cases   usmle forums
50 star ccs cases usmle forums
 
Gastroenterology
Gastroenterology Gastroenterology
Gastroenterology
 
Dr. Red Sample C C S Casesfor U S M L E Step3.Doc
Dr. Red  Sample C C S Casesfor U S M L E Step3.DocDr. Red  Sample C C S Casesfor U S M L E Step3.Doc
Dr. Red Sample C C S Casesfor U S M L E Step3.Doc
 
Thrombophilias
ThrombophiliasThrombophilias
Thrombophilias
 
Carcinoma of unknown primary
Carcinoma of unknown primaryCarcinoma of unknown primary
Carcinoma of unknown primary
 
Bladder cancer
Bladder cancerBladder cancer
Bladder cancer
 
Thrombocytopenia
ThrombocytopeniaThrombocytopenia
Thrombocytopenia
 
Acute Lymphoblastic Lymphoma
Acute Lymphoblastic LymphomaAcute Lymphoblastic Lymphoma
Acute Lymphoblastic Lymphoma
 
Cutaneous lymphomas
Cutaneous lymphomasCutaneous lymphomas
Cutaneous lymphomas
 
Neurology[1]
Neurology[1]Neurology[1]
Neurology[1]
 

Similar a Archer Neurology for USMLE Step 3

Supra ventricular tachycardia
Supra ventricular tachycardiaSupra ventricular tachycardia
Supra ventricular tachycardia
Tamil Mani
 
Atrial fibrillation management
Atrial fibrillation managementAtrial fibrillation management
Atrial fibrillation management
Basem Enany
 
Anaesthetic management of Abdominal aortic aneurysms
Anaesthetic management of Abdominal aortic aneurysmsAnaesthetic management of Abdominal aortic aneurysms
Anaesthetic management of Abdominal aortic aneurysms
Abhijit Nair
 

Similar a Archer Neurology for USMLE Step 3 (20)

Acute Coronary Syndromes
Acute Coronary Syndromes Acute Coronary Syndromes
Acute Coronary Syndromes
 
Stroke prevention (secondary).pptx
Stroke prevention (secondary).pptxStroke prevention (secondary).pptx
Stroke prevention (secondary).pptx
 
Ischaemic stroke cme
Ischaemic stroke cmeIschaemic stroke cme
Ischaemic stroke cme
 
Subarachnoid hemorrage –eso guidelines for management
Subarachnoid hemorrage –eso guidelines for managementSubarachnoid hemorrage –eso guidelines for management
Subarachnoid hemorrage –eso guidelines for management
 
Atrial fibrilation diagnosis and management updated guidline. NICE 2021.
Atrial fibrilation diagnosis and management updated guidline. NICE 2021.Atrial fibrilation diagnosis and management updated guidline. NICE 2021.
Atrial fibrilation diagnosis and management updated guidline. NICE 2021.
 
Supra ventricular tachycardia
Supra ventricular tachycardiaSupra ventricular tachycardia
Supra ventricular tachycardia
 
Atrial Fibrillation 2016
Atrial Fibrillation 2016Atrial Fibrillation 2016
Atrial Fibrillation 2016
 
Atrial fibrillation management
Atrial fibrillation managementAtrial fibrillation management
Atrial fibrillation management
 
Hypertensive emergencies
Hypertensive emergenciesHypertensive emergencies
Hypertensive emergencies
 
MANAGEMENT OF ATRIAL FIBRILLATION.pptx
MANAGEMENT OF ATRIAL FIBRILLATION.pptxMANAGEMENT OF ATRIAL FIBRILLATION.pptx
MANAGEMENT OF ATRIAL FIBRILLATION.pptx
 
Atrial fibrillation 2014
Atrial fibrillation 2014Atrial fibrillation 2014
Atrial fibrillation 2014
 
Hypertensive emergencies
Hypertensive emergenciesHypertensive emergencies
Hypertensive emergencies
 
Anaesthesia and ihd
Anaesthesia and ihdAnaesthesia and ihd
Anaesthesia and ihd
 
Lec 8 atrial fibrillation for mohs
Lec 8 atrial fibrillation for mohsLec 8 atrial fibrillation for mohs
Lec 8 atrial fibrillation for mohs
 
Anaesthetic management of Abdominal aortic aneurysms
Anaesthetic management of Abdominal aortic aneurysmsAnaesthetic management of Abdominal aortic aneurysms
Anaesthetic management of Abdominal aortic aneurysms
 
Stroke CVa.pptx
Stroke CVa.pptxStroke CVa.pptx
Stroke CVa.pptx
 
Pharmacology_Anti-thrombotics- Antiplatelet drugs.pptx
Pharmacology_Anti-thrombotics- Antiplatelet drugs.pptxPharmacology_Anti-thrombotics- Antiplatelet drugs.pptx
Pharmacology_Anti-thrombotics- Antiplatelet drugs.pptx
 
Stroke
StrokeStroke
Stroke
 
stroke.pptx
stroke.pptxstroke.pptx
stroke.pptx
 
current stroke management guideline.pptx
current stroke management guideline.pptxcurrent stroke management guideline.pptx
current stroke management guideline.pptx
 

Más de Archer Review USMLE and NCLEX

Más de Archer Review USMLE and NCLEX (18)

Endocrine Archer NCLEX course Webinar
Endocrine Archer NCLEX course WebinarEndocrine Archer NCLEX course Webinar
Endocrine Archer NCLEX course Webinar
 
Safety and infection control - Archer NCLEX webinars
Safety and infection control - Archer NCLEX webinarsSafety and infection control - Archer NCLEX webinars
Safety and infection control - Archer NCLEX webinars
 
Archer NCLEX Webinars - Diets and Nutrition crash course
Archer NCLEX Webinars - Diets and Nutrition crash courseArcher NCLEX Webinars - Diets and Nutrition crash course
Archer NCLEX Webinars - Diets and Nutrition crash course
 
Rapid Content Prep - NCLEX- Archer Review
Rapid Content Prep - NCLEX- Archer ReviewRapid Content Prep - NCLEX- Archer Review
Rapid Content Prep - NCLEX- Archer Review
 
Archer NCLEX Rapid Review - Full Content Syllabus - Two days
Archer NCLEX Rapid Review - Full Content Syllabus - Two daysArcher NCLEX Rapid Review - Full Content Syllabus - Two days
Archer NCLEX Rapid Review - Full Content Syllabus - Two days
 
Cardiology and EKGs - Archer NCLEX crash course/ webinar
Cardiology and EKGs - Archer NCLEX crash course/ webinarCardiology and EKGs - Archer NCLEX crash course/ webinar
Cardiology and EKGs - Archer NCLEX crash course/ webinar
 
Fluids and electrolytes Archer NCLEX content review webinar
Fluids and electrolytes  Archer NCLEX content review webinarFluids and electrolytes  Archer NCLEX content review webinar
Fluids and electrolytes Archer NCLEX content review webinar
 
Archer NCLEX Pharmacology crash course - Webinar
Archer NCLEX Pharmacology crash course - WebinarArcher NCLEX Pharmacology crash course - Webinar
Archer NCLEX Pharmacology crash course - Webinar
 
Archer NCLEX Review - Electrolyte imbalances
Archer NCLEX Review - Electrolyte imbalancesArcher NCLEX Review - Electrolyte imbalances
Archer NCLEX Review - Electrolyte imbalances
 
Archer USMLE Step 3 Nephrology 2019
Archer USMLE Step 3 Nephrology 2019Archer USMLE Step 3 Nephrology 2019
Archer USMLE Step 3 Nephrology 2019
 
Endocrinology archer step3 lectures
Endocrinology   archer step3 lecturesEndocrinology   archer step3 lectures
Endocrinology archer step3 lectures
 
Infectious disease Archer USMLE Step3 Review Lectures
Infectious disease   Archer USMLE Step3 Review LecturesInfectious disease   Archer USMLE Step3 Review Lectures
Infectious disease Archer USMLE Step3 Review Lectures
 
Archer step 3 ccs workshop 2019
Archer step 3 ccs workshop 2019Archer step 3 ccs workshop 2019
Archer step 3 ccs workshop 2019
 
Plasma cell disorders ppt
Plasma cell disorders pptPlasma cell disorders ppt
Plasma cell disorders ppt
 
Several Samples - Personal Statements
Several Samples - Personal StatementsSeveral Samples - Personal Statements
Several Samples - Personal Statements
 
Internal medicine Personal Statement
Internal medicine Personal StatementInternal medicine Personal Statement
Internal medicine Personal Statement
 
Acing the residency interview
Acing the residency interviewAcing the residency interview
Acing the residency interview
 
How to nail that Residency interview?
How to nail that Residency interview?How to nail that Residency interview?
How to nail that Residency interview?
 

Último

Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
ciinovamais
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
QucHHunhnh
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
kauryashika82
 

Último (20)

Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdf
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Asian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptxAsian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptx
 
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural ResourcesEnergy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
 
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIFood Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SD
 

Archer Neurology for USMLE Step 3

  • 1. Neurology Archer USMLE Step3 Reviews www.CcsWorkshop.com Archer Slides are intended for use with Archer USMLE step 3 video lectures. Hence, most slides are very brief summaries of the concepts which will be addressed in a detailed way with focus on High-yield concepts in the Video lectures. These slides are only SAMPLES
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 20.
  • 21.
  • 23.
  • 24. Meningitis – Emperical therapy Predisposing Factor AGE Common Bacterial Pathogens Antimicrobial Rx <1 month Streptococcus agalactiae, Escherichia coli, Listeria monocytogenes, Klebsiella species Ampicillin plus cefotaxime or ampicillin plus an aminoglycoside 1 - 23 months Streptococcus pneumoniae , Neisseria meningitidis, S. agalactiae, Haemophilus influenzae, E. coli Vancomycin plus a third-generation cephalosporin 2- 50 years N . meningitidis, S. pneumoniae Vancomycin plus a third-generation cephalosporin >50 years S. pneumoniae, N. meningitidis, L. monocytogenes , aerobic gram-negative bacilli Vancomycin plus ampicillin plus a third-generation cephalosporin
  • 25. Meningitis – Emperical therapy Predisposing Factor HEAD TRAUMA Common Bacterial Pathogens Antimicrobial Rx   Basilar skull fracture S. pneumoniae, H. influenzae, group A -hemolytic streptococci Vancomycin plus a third-generation cephalosporin Penetrating trauma Staphylococcus aureus, coagulase-negative staphylococci (especially Staphylococcus epidermidis), aerobic gram-negative bacilli (including Pseudomonas aeruginosa ) Vancomycin plus cefepime, vancomycin plus ceftazidime, or vancomycin plus meropenem  YOU ARE Adding an antipseudomonal antibiotic. Postneurosurgery Aerobic gram-negative bacilli (including P. aeruginosa ), S . aureus , coagulase-negative staphylococci (especially S. epidermidis) Vancomycin plus cefepime, vancomycin plus ceftazidime, or vancomycin plus meropenem CSF shunt Coagulase-negative staphylococci (especially S. epidermidis), S. aureus, aerobic gram-negative bacilli (including P. aeruginosa ), Propionibacterium acnes Vancomycin plus cefepime,c vancomycin plus ceftazidime,c or vancomycin plus meropenem
  • 26. Fall Prevention - Elderly
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33. Headaches Migraines Tension headaches Cluster Headaches Temporal arteritis Chronic daily headache Analgesic Rebound Headache Post Traumatic Headache Menstrual Migraine Sinusitis
  • 35.
  • 36.
  • 37. Post-test Probabilities of Migraine Based on the Number of Migraine Features on History Compared to a Reference Standard of Headache Expert Neurologist Clinical Evaluation Result Pretest Probability (%)† 20 50 80 0, 1, or 2 migraine symptoms* 5 15 50 3 migraine symptoms* 75 94 99 4 or 5 migraine symptoms* 90 96 >99
  • 38.
  • 39.
  • 42.
  • 43.
  • 44.
  • 46.
  • 47.
  • 48.
  • 49.
  • 51.
  • 52.
  • 53.
  • 54.
  • 56.
  • 57.
  • 58. Chronic Daily Headache Rebound Headaches Analgesic overuse headaches Chronic Migraine
  • 59.
  • 60. CDH – d/d Primary Headaches Headache Duration > 4hrs Headache Duration < 4hrs Chronic (transformed) migraine Strictly unilateral-prominent autonomic features(SUNCT) Chronic tension-type headache Cluster headache New daily persistent headache Paroxysmal hemicrania Hemicrania continua Trigeminal neuralgia Cough headache Benign exertional headache Headache associated with sexual activity
  • 61.
  • 62.
  • 63.
  • 64.
  • 65.
  • 66. Benign Intracranial Hypertension Pseudotumor Cerebrii
  • 67.
  • 68.
  • 70.
  • 71.
  • 72.
  • 73.
  • 74.
  • 75.
  • 77.
  • 78.
  • 79.
  • 80.
  • 81. Revised McDonald Criteria for Diagnosis of MS
  • 82. Definition of positive MRI—3 out of 4 of the following: 1 gadolinium-enhancing lesion or 9 T2 hyperintense lesions if no gadolinium-enhancing lesion; 1 or more infratentorial lesions; 1 or more juxtacortical lesions; 3 or more periventricular lesions. Note: A spinal cord lesion can be considered equivalent to an infratentorial lesion in the brain. Thus, an enhancing spinal cord lesion is considered to be equivalent to an enhancing brain lesion, and individual spinal cord lesions can contribute together with individual brain lesions to reach the required number of T2 lesions. Clinical (Attacks) Objective Lesions Additional Requirements to Make Diagnosis 2 or more 2 or more None; additional evidence desirable but must be consistent with MS 2 or more 1 Dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS or further clinical attack involving different site 1 2 or more Dissemination in time by MRI or second clinical attack 1 (monosymptomatic) 1 Dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS AND Dissemination in time by MRI or second clinical attack 1 (progression from onset) 1 One year of disease progression (retrospectively or prospectively determined) AND Two of the following: a) Positive brain MRI (nine T2 lesions or four or more T2 lesions with positive visual evoked potentials) b) Positive spinal cord MRI (two focal T2 lesions) c) Positive CSF
  • 83.
  • 84.
  • 85.
  • 86.
  • 88.
  • 89.
  • 90.
  • 91.
  • 92.
  • 93.
  • 94.
  • 95. ALS
  • 96.
  • 97.
  • 98.
  • 99.
  • 100.
  • 101. Neurosyphilis Refer to ID slides under “Syphilis”
  • 102. Delirium Refer to Psychaitry Slides
  • 104.
  • 105.
  • 106.
  • 107.
  • 108.
  • 109.
  • 110.
  • 111.
  • 112.
  • 113.
  • 114.
  • 115.
  • 116.
  • 117.
  • 118.
  • 119.
  • 120.
  • 128.
  • 129.